Cancer Research Cancer Epigenetics  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aguirre-Ghiso, J. A.
Right arrow Articles by Ossowski, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aguirre-Ghiso, J. A.
Right arrow Articles by Ossowski, L.
[Cancer Research 63, 1684-1695, April 1, 2003]
© 2003 American Association for Cancer Research


Tumor Biology

ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK1

Julio A. Aguirre-Ghiso, Yeriel Estrada, David Liu and Liliana Ossowski2

Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029

After dissemination from a primary tumor, cancer cells may resume growth, leading to overt metastasis, or enter a state of protracted dormancy. However, mechanisms that determine their fate, or markers that predict it, are mostly unavailable. We previously showed that in HEp3 human head and neck carcinoma, the extracellular signal-regulated kinase (ERK)MAPK/p38SAPK activity ratio predicts whether the cells will proliferate or enter a state of dormancy in vivo. The proproliferative balance of high ERK/p38 ratio was induced by high urokinase (uPA) receptor (uPAR) expression, which activated {alpha}5ß1-integrin and epidermal growth factor receptor. This signaling pathway was additionally enhanced by uPA binding to uPAR and fibronectin binding to {alpha}5ß1-integrin. We tested whether the ERK/p38 balance is predictive of in vivo behavior in other cancer cell types and whether altering the balance will shift their phenotype between proliferation and dormancy. ERK and p38 activities were determined using either phospho-specific monoclonal antibodies or a trans-reporting system where GAL4-Elk and GAL4-CHOP trans-activation of luciferase gene served as reporters for ERK and p38 activities, respectively. We show that in breast, prostate, melanoma, and fibrosarcoma cell lines, the level of active phospho-ERK and the ERK/p38 activity ratio predict for the in vivo behavior in ~90% of the cell lines tested. Modulation of ERK/p38 activity ratio by multiple pharmacological and genetic interventions confirms that high ERK/p38 ratio favors tumor growth, whereas high p38/ERK ratio induces tumor growth arrest (dormancy) in vivo and that ERK is negatively regulated by p38. A melanoma cell line appeared to have developed an escape mechanism to avoid the growth inhibitory effect of high p38 activity. Mechanistic analysis implicated high uPAR expression and its interaction with and activation of {alpha}5ß1-integrin as determinants of the in vivo growth promoting high ERK/p38 ratio in several cell lines. The small GTPase, Cdc42, was implicated in activation of p38 and growth arrest. These results suggest that even cells that originate in advanced cancers retain a degree of dependence on surface receptors and matrix for their proliferative signals in vivo and provide a therapeutic opportunity to change their phenotype from tumorigenic to dormant.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
X. Cheng, Z. Shen, L. Yin, S.-H. Lu, and Y. Cui
ECRG2 Regulates Cell Migration/Invasion through Urokinase-type Plasmin Activator Receptor (uPAR)/{beta}1 Integrin Pathway
J. Biol. Chem., November 6, 2009; 284(45): 30897 - 30906.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. P. Adam, A. George, D. Schewe, P. Bragado, B. V. Iglesias, A. C. Ranganathan, A. Kourtidis, D. S. Conklin, and J. A. Aguirre-Ghiso
Computational Identification of a p38SAPK-Regulated Transcription Factor Network Required for Tumor Cell Quiescence
Cancer Res., July 15, 2009; 69(14): 5664 - 5672.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
L. Ying, A. Lau, C. M. Alvira, R. West, G. M. Cann, B. Zhou, C. Kinnear, E. Jan, P. Sarnow, M. Van de Rijn, et al.
LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor
J. Cell Sci., May 1, 2009; 122(9): 1441 - 1451.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M. Schewe and J. A. Aguirre-Ghiso
Inhibition of eIF2{alpha} Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy
Cancer Res., February 15, 2009; 69(4): 1545 - 1552.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. M. Schewe and J. A. Aguirre-Ghiso
ATF6{alpha}-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
PNAS, July 29, 2008; 105(30): 10519 - 10524.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A Vincent-Salomon, F C Bidard, and J Y Pierga
Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Sun, F. Wu, F. Sun, and P. Huang
Adenosine Promotes IL-6 Release in Airway Epithelia
J. Immunol., March 15, 2008; 180(6): 4173 - 4181.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. K. Pulukuri, B. Gorantla, and J. S. Rao
Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator
J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Zheng, X.-X. Cui, G. E. Avila, M.-T. Huang, Y. Liu, J. Patel, A. N. T. Kong, R. Paulino, W. J. Shih, Y. Lin, et al.
Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice
Clin. Cancer Res., September 15, 2007; 13(18): 5480 - 5487.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
J.F. Schindler, J.B. Monahan, and W.G. Smith
p38 Pathway Kinases as Anti-inflammatory Drug Targets
Journal of Dental Research, September 1, 2007; 86(9): 800 - 811.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-H. Hsieh, T.-T. Wu, C.-Y. Huang, Y.-S. Hsieh, J.-M. Hwang, and J.-Y. Liu
p38 Mitogen-Activated Protein Kinase Pathway Is Involved in Protein Kinase C{alpha}-Regulated Invasion in Human Hepatocellular Carcinoma Cells
Cancer Res., May 1, 2007; 67(9): 4320 - 4327.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. G. Papatsoris, M. V. Karamouzis, and A. G. Papavassiliou
The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics
Mol. Cancer Ther., March 1, 2007; 6(3): 811 - 819.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Wei, C.-H. Tang, Y. Kim, L. Robillard, F. Zhang, M. C. Kugler, and H. A. Chapman
Urokinase Receptors Are Required for {alpha}5beta1 Integrin-mediated Signaling in Tumor Cells
J. Biol. Chem., February 9, 2007; 282(6): 3929 - 3939.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. K. Pulukuri, N. Estes, J. Patel, and J. S. Rao
Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer
Cancer Res., February 1, 2007; 67(3): 930 - 939.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Yin, F. Vreeland, L. J. Schaaf, R. Millham, B. A. Duncan, and A. Sharma
Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy
Clin. Cancer Res., February 1, 2007; 13(3): 1000 - 1009.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. Z. Hashmi, W. Hakim, E. A. Kruglov, A. Watanabe, W. Watkins, J. A. Dranoff, and W. Z. Mehal
Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells
Am J Physiol Gastrointest Liver Physiol, January 1, 2007; 292(1): G395 - G401.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick
Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression
Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
L.-J. Zhao, X.-L. Zhang, P. Zhao, J. Cao, M.-M. Cao, S.-Y. Zhu, H.-Q. Liu, and Z.-T. Qi
Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line
J. Leukoc. Biol., August 1, 2006; 80(2): 424 - 432.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. Madsen, E. I. Deryugina, S. Niessen, B. F. Cravatt, and J. P. Quigley
Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation
J. Biol. Chem., June 9, 2006; 281(23): 15997 - 16005.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Chaurasia, J. A. Aguirre-Ghiso, O. D. Liang, H. Gardsvoll, M. Ploug, and L. Ossowski
A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with {alpha}5beta1 Integrin and Tumor Growth
J. Biol. Chem., May 26, 2006; 281(21): 14852 - 14863.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. K. Rasiah, J. G. Kench, M. Gardiner-Garden, A. V. Biankin, D. Golovsky, P. C. Brenner, R. Kooner, G. F. O'Neill, J. J. Turner, W. Delprado, et al.
Aberrant neuropeptide y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.
Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 711 - 716.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
E. A. Kruglov, R. A. Nathanson, T. Nguyen, and J. A. Dranoff
Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts
Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G765 - G771.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. N. Naumov, E. Bender, D. Zurakowski, S.-Y. Kang, D. Sampson, E. Flynn, R. S. Watnick, O. Straume, L. A. Akslen, J. Folkman, et al.
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.
J Natl Cancer Inst, March 1, 2006; 98(5): 316 - 325.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. A. Hickson, D. Huo, D. J. Vander Griend, A. Lin, C. W. Rinker-Schaeffer, and S. D. Yamada
The p38 Kinases MKK4 and MKK6 Suppress Metastatic Colonization in Human Ovarian Carcinoma
Cancer Res., February 15, 2006; 66(4): 2264 - 2270.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. C. Ranganathan, L. Zhang, A. P. Adam, and J. A. Aguirre-Ghiso
Functional Coupling of p38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase-Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells
Cancer Res., February 1, 2006; 66(3): 1702 - 1711.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Vander Griend, M. Kocherginsky, J. A. Hickson, W. M. Stadler, A. Lin, and C. W. Rinker-Schaeffer
Suppression of Metastatic Colonization by the Context-Dependent Activation of the c-Jun NH2-Terminal Kinase Kinases JNKK1/MKK4 and MKK7
Cancer Res., December 1, 2005; 65(23): 10984 - 10991.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Pulukuri, C. S. Gondi, S. S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J. S. Rao
RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo
J. Biol. Chem., October 28, 2005; 280(43): 36529 - 36540.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. J. Renukaradhya, T. J. R. Webb, M. A. Khan, Y. L. Lin, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz
Virus-Induced Inhibition of CD1d1-Mediated Antigen Presentation: Reciprocal Regulation by p38 and ERK
J. Immunol., October 1, 2005; 175(7): 4301 - 4308.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Y. Zhu, X. Zhong, S. Zheng, Z. Ge, Q. Du, and S. Zhang
Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade
Carcinogenesis, July 1, 2005; 26(7): 1207 - 1214.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Gargiulo, I. Longanesi-Cattani, K. Bifulco, P. Franco, R. Raiola, P. Campiglia, P. Grieco, G. Peluso, M. P. Stoppelli, and M. V. Carriero
Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide
J. Biol. Chem., July 1, 2005; 280(26): 25225 - 25232.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. E. McMullen, P. W. Bryant, C. C. Glembotski, P. A. Vincent, and K. M. Pumiglia
Activation of p38 Has Opposing Effects on the Proliferation and Migration of Endothelial Cells
J. Biol. Chem., June 3, 2005; 280(22): 20995 - 21003.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Jo, K. S. Thomas, N. Marozkina, T. J. Amin, C. M. Silva, S. J. Parsons, and S. L. Gonias
Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator
J. Biol. Chem., April 29, 2005; 280(17): 17449 - 17457.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. F. Deroanne, D. Hamelryckx, T. T. G. Ho, C. A. Lambert, P. Catroux, C. M. Lapiere, and B. V. Nusgens
Cdc42 downregulates MMP-1 expression by inhibiting the ERK1/2 pathway
J. Cell Sci., March 15, 2005; 118(6): 1173 - 1183.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. M. Kumar, G. Acs, D. Fang, M. Herlyn, D. E. Elder, and X. Xu
Functional Erythropoietin Autocrine Loop in Melanoma
Am. J. Pathol., March 1, 2005; 166(3): 823 - 830.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Lou, S. O'Reilly, H. Liang, V. M. Maher, S. D. Sleight, and J. J. McCormick
Down-Regulation of Overexpressed Sp1 Protein in Human Fibrosarcoma Cell Lines Inhibits Tumor Formation
Cancer Res., February 1, 2005; 65(3): 1007 - 1017.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
Y. Wei, R.-P. Czekay, L. Robillard, M. C. Kugler, F. Zhang, K. K. Kim, J.-p. Xiong, M. J. Humphries, and H. A. Chapman
Regulation of {alpha}5{beta}1 integrin conformation and function by urokinase receptor binding
J. Cell Biol., January 31, 2005; 168(3): 501 - 511.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. J. Waters and B. L. Conway-Campbell
The oncogenic potential of autocrine human growth hormone in breast cancer
PNAS, October 19, 2004; 101(42): 14992 - 14993.
[Full Text] [PDF]


Home page
Cancer Res.Home page
J. A. Aguirre-Ghiso, L. Ossowski, and S. K. Rosenbaum
Green Fluorescent Protein Tagging of Extracellular Signal-Regulated Kinase and p38 Pathways Reveals Novel Dynamics of Pathway Activation during Primary and Metastatic Growth
Cancer Res., October 15, 2004; 64(20): 7336 - 7345.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. A. Dranoff, M. Ogawa, E. A. Kruglov, M. D. A. Gaca, J. Sevigny, S. C. Robson, and R. G. Wells
Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells
Am J Physiol Gastrointest Liver Physiol, August 1, 2004; 287(2): G417 - G424.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Qi, J. Tang, R. Pramanik, R. M. Schultz, S. Shirasawa, T. Sasazuki, J. Han, and G. Chen
p38 MAPK Activation Selectively Induces Cell Death in K-ras-mutated Human Colon Cancer Cells through Regulation of Vitamin D Receptor
J. Biol. Chem., May 21, 2004; 279(21): 22138 - 22144.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Liu, S. Yin, N. Reddy, C. Spencer, and S. Sheng
Bax Mediates the Apoptosis-Sensitizing Effect of Maspin
Cancer Res., March 1, 2004; 64(5): 1703 - 1711.
[Abstract] [Full Text] [PDF]


Home page
aacrmtgHome page
L. Ossowski, J. Aguirre Ghiso, D. Liu, Y. Estrada, and S. Rosenbaum
The role of ERK and p38 in regulation of tumor dormancy.
AACR Meeting Abstracts, March 1, 2004; 2004(1): 1318 - 1319.
[Abstract]


Home page
J. Cell Sci.Home page
R. M. Klein, M. Zheng, A. Ambesi, L. Van De Water, and P. J. McKeown-Longo
Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin
J. Cell Sci., November 15, 2003; 116(22): 4663 - 4674.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. R. Welch and K. W. Hunter
A New Member of the Growing Family of Metastasis Suppressors Identified in Prostate Cancer
J Natl Cancer Inst, June 18, 2003; 95(12): 839 - 841.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.